Biomerica (NASDAQ: BMRA) grants B. Riley board designee in $2.23M raise
Rhea-AI Filing Summary
Biomerica, Inc. (BMRA) entered into a private placement on August 20, 2026, agreeing to issue 1,393,705 shares of common stock at $1.60 per share, for aggregate gross proceeds of approximately $2.23 million. The closing occurred on August 26, 2026.
The investors include institutional and individual purchasers such as B. Riley Principal Capital, LLC and certain Biomerica directors and executive officers. For so long as the B. Riley purchasers collectively hold at least 10% of the voting power of Biomerica’s outstanding common stock, B. Riley Principal Capital, LLC may designate one representative for election or appointment to the Board, subject to Nasdaq rules. Directors and certain executive officers must enter 180‑day lock-up agreements.
Biomerica also entered into a Registration Rights Agreement, committing to file a resale registration statement within 30 days of closing and to seek effectiveness within 30 days (or 60 days if subject to full SEC review), with liquidated damages of 1.0% of a purchaser’s subscription amount for certain registration failures, capped at 5.0%.
Positive
- None.
Negative
- None.
Filing Explained
The August 26 closing completed the sale of
8-K Event Classification
3 items: 1.01, 3.02, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Shares issued in Private Placement: 1,393,705 shares
Purchase price per Share: $1.60 per Share
Aggregate gross proceeds: approximately $2.23 million
+5 more
8 metrics
Shares issued in Private Placement
1,393,705 shares
Common stock issued pursuant to the Securities Purchase Agreement
Purchase price per Share
$1.60 per Share
Price for each share of common stock in the private placement
Aggregate gross proceeds
approximately $2.23 million
Total gross proceeds from the private placement
B. Riley board designation threshold
10% of voting power
Minimum aggregate beneficial ownership for B. Riley purchasers to retain board designee right
Liquidated damages rate
1.0% of aggregate purchase price
Per occurrence for certain registration failures under the Registration Rights Agreement
Liquidated damages cap
5.0% of subscription amount
Maximum aggregate cap on liquidated damages per purchaser
Lock-up period
180 days
Duration after closing during which certain insiders are restricted from transfers
Registration filing deadline
30 calendar days from Closing Date
Deadline to file resale registration statement with the SEC
Key Terms
Private Placement, Registration Rights Agreement, Section 4(a)(2) of the Securities Act, Rule 506 of Regulation D, +1 more
5 terms
Private Placement financial
"for aggregate gross proceeds of approximately $2.23 million (the “Private Placement”)."
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Registration Rights Agreement regulatory
"the Company entered into a Registration Rights Agreement with the Purchasers"
A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.
Section 4(a)(2) of the Securities Act regulatory
"in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act"
A legal exemption that allows a company to sell securities directly to a limited group of buyers without registering the offering with the Securities and Exchange Commission. Think of it like a private sale among known parties rather than a public auction: it can speed fundraising and reduce disclosure requirements, but it also means less public information, lower liquidity and resale restrictions—factors investors should consider when weighing risk and exit options.
Rule 506 of Regulation D regulatory
"and/or Rule 506 of Regulation D promulgated thereunder."
Rule 506 of Regulation D is a U.S. Securities and Exchange Commission exemption that lets companies sell securities privately without registering them with the SEC, similar to a private party invitation rather than a public auction. It matters to investors because it determines how much information they’ll receive, who can buy (accredited vs. non-accredited), whether public advertising is allowed, and how easily the investment can be resold — all factors that affect risk, transparency and liquidity.
liquidated damages financial
"the Company is obligated to pay the Purchasers liquidated damages equal to 1.0%"
A pre-agreed sum that one party must pay if it breaks a contract, chosen so both sides avoid arguing over the exact amount of loss later. Think of it like a fixed cancellation fee for a reservation: it makes potential costs predictable. For investors, liquidated damages matter because they create a known financial liability that can affect cash flow, contract risk, balance-sheet exposure and deal valuations.
FAQ
What capital did BIOMERICA INC (BMRA) raise in the August 2026 private placement?
Biomerica raised aggregate gross proceeds of approximately $2.23 million by issuing 1,393,705 shares of common stock at $1.60 per share in a private placement agreed on August 20, 2026, which closed on August 26, 2026.
Who participated in the August 2026 BMRA private placement?
The purchasers included certain institutional and individual investors, among them B. Riley Principal Capital, LLC, as well as certain members of Biomerica’s Board of Directors and executive officers, as identified in the Securities Purchase Agreement.
What board rights did B. Riley obtain in the BMRA transaction?
For so long as the B. Riley purchasers beneficially own securities representing at least 10% of the voting power of Biomerica’s outstanding common stock, B. Riley Principal Capital, LLC may designate one representative for election or appointment to Biomerica’s Board, subject to Nasdaq rules.
What lock-up terms apply to Biomerica insiders after the private placement?
Biomerica’s directors and certain executive officers are required to enter into lock-up agreements that restrict specified transfers of company securities for a period of 180 days following the August 26, 2026 closing, subject to the terms and exceptions in those agreements.
What liquidated damages can BMRA owe if it misses registration deadlines?
If Biomerica fails to meet certain filing or effectiveness obligations under the Registration Rights Agreement, it must pay liquidated damages equal to 1.0% of a purchaser’s aggregate purchase price, subject to a maximum aggregate cap of 5.0% of that purchaser’s subscription amount.
AI-generated analysis. How Rhea-AI works. Not financial advice.
